Short title: 2014 UK HAE Consensus

[1]  A. Bygum.  Hereditary angioedema - consequences of a new treatment paradigm in Denmark. , 2014, Acta dermato-venereologica.

[2]  J. Bernstein,et al.  Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. , 2014, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[3]  L. Mallbris,et al.  Quantifying the burden of disease and perceived health state in patients with hereditary angioedema in Sweden. , 2014, Allergy and asthma proceedings.

[4]  P. Williams,et al.  A UK national audit of hereditary and acquired angioedema , 2014, Clinical and experimental immunology.

[5]  P. Schmid‐Grendelmeier,et al.  Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST‐2 open‐label study , 2013, Allergy.

[6]  A. Banerji.  The burden of illness in patients with hereditary angioedema. , 2013, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[7]  A. Gompel,et al.  Hereditary angioedema with C1 inhibitor deficiency: clinical presentation and quality of life of 193 French patients. , 2013, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[8]  J. Bernstein,et al.  US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. , 2013, The journal of allergy and clinical immunology. In practice.

[9]  J Dempster,et al.  In pursuit of excellence: an integrated care pathway for C1 inhibitor deficiency , 2013, Clinical and experimental immunology.

[10]  T. Craig,et al.  Review of Recent Guidelines and Consensus Statements on Hereditary Angioedema Therapy with Focus on Self-Administration , 2013, International Archives of Allergy and Immunology.

[11]  A. Gompel,et al.  Benefits of progestin contraception in non‐allergic angioedema , 2013, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[12]  R. Lockey,et al.  Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study. , 2013, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[13]  A. Sheffer,et al.  Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks. , 2013, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[14]  J. Bernstein.  HAE update: epidemiology and burden of disease. , 2013, Allergy and asthma proceedings.

[15]  R. Lockey,et al.  WAO Guideline for the Management of Hereditary Angioedema , 2012, The World Allergy Organization journal.

[16]  M. Cicardi,et al.  Hereditary angioedema with normal C1 inhibitor function: consensus of an international expert panel. , 2012, Allergy and asthma proceedings.

[17]  B. Zuraw,et al.  Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. , 2012, The American journal of medicine.

[18]  K. Bork,et al.  Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. , 2012, The Journal of allergy and clinical immunology.

[19]  M. Triggiani,et al.  Icatibant treatment for acquired C1‐inhibitor deficiency: a real‐world observational study , 2012, Allergy.

[20]  T. Machnig,et al.  Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks. , 2012, Allergy and asthma proceedings.

[21]  M. Cicardi,et al.  Hereditary angio-oedema , 2012, The Lancet.

[22]  Tom Bowen,et al.  International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. , 2012, The Journal of allergy and clinical immunology.

[23]  M. Triggiani,et al.  Evidence‐based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group , 2012, Allergy.

[24]  J. Nuijens,et al.  Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. , 2010, The Journal of allergy and clinical immunology.

[25]  W. Lumry,et al.  The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depression. , 2010, Allergy and asthma proceedings.

[26]  J. Bernstein,et al.  Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. , 2010, The New England journal of medicine.

[27]  A. Sheffer,et al.  Ecallantide for the treatment of acute attacks in hereditary angioedema. , 2010, The New England journal of medicine.

[28]  William H. Yang,et al.  Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. , 2010, The New England journal of medicine.

[29]  P. Keith,et al.  2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema , 2010, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.

[30]  M. Gompels,et al.  HAE international home therapy consensus document , 2010, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.

[31]  W. Lumry,et al.  EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. , 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[32]  A. Bygum,et al.  Hereditary angio‐oedema in Denmark: a nationwide survey , 2009, The British journal of dermatology.

[33]  J. Bernstein,et al.  Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. , 2009, The Journal of allergy and clinical immunology.

[34]  K. Andersen,et al.  Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. , 2009, European journal of dermatology : EJD.

[35]  H. Longhurst,et al.  Clinical Immunology Review Series: An approach to the patient with angio‐oedema , 2009, Clinical and experimental immunology.

[36]  M. Cicardi,et al.  Angioedema due to acquired C1-inhibitor deficiency: a bridging condition between autoimmunity and lymphoproliferation. , 2008, Autoimmunity reviews.

[37]  William H. Yang,et al.  Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[38]  K. Khair,et al.  C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option , 2006, Clinical and experimental immunology.

[39]  M. Levi,et al.  Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. , 2006, The Journal of allergy and clinical immunology.

[40]  M. López-Trascasa,et al.  Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. , 2005, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[41]  M. Gompels,et al.  C1 inhibitor deficiency: consensus document , 2005, Clinical and experimental immunology.

[42]  K. Bork,et al.  Asphyxiation by laryngeal edema in patients with hereditary angioedema. , 2000, Mayo Clinic proceedings.

[43]  M. Cicardi,et al.  Hereditary and Acquired C1‐Inhibitor Deficiency: Biological and Clinical Characteristics in 235 Patients , 1992, Medicine.